Drug Profile


Alternative Names: CDX-1127

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; Oncothyreon; University of California at San Francisco; University of Virginia
  • Class Antigens; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD27 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours
  • Phase I/II Renal cell carcinoma
  • Phase I Glioma; Haematological malignancies; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 31 Jan 2017 The National Cancer Institute plans a phase II trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03038672)
  • 01 Jan 2017 Phase-I clinical trials in Glioma (Combination therapy, Second-line therapy or greater, Neoadjuvant therapy) in USA (IV) (NCT02924038)
  • 30 Nov 2016 Celldex Therapeutics terminates a pilot phase I trial in Prostate cancer (Combination therapy) in USA due to low accrual (NCT02284971)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top